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a b s t r a c t
The purpose of this work was to assess the ability of recombinant hepatitis B vaccine,
encapsulated in alginate-coated chitosan nanoparticles, to induce local and systemic
immune responses following oral vaccination. The antigen was administered either alone
or in combination with the immunopotentiator, synthetic oligodeoxynucleotide contain-
ing immunostimulatory CpG motif (CpG ODN) as adjuvant, and associated or not with
the alginate-coated chitosan nanoparticles. After two immunizations the group I (HBsAg
associated with nanoparticles) and the group VI (HBsAg and CpG, both associated with
nanoparticles) showed enhanced immune responses. Both groups showed significant higher
values of the CD69 expression in CD4+ and CD8+ T-lymphocytes and lower values of this
marker in B lymphocytes. Moreover, a strongest proliferative response of the splenocytes,
ex vivo stimulated with concanavalin A, was observed in the same groups. Although withnanoparticles
Vaccines
a presence of non-responder mice within the groups, only mice of the groups I and VI
elicited the generation of anti-HBsAg antibodies detected in serum (IgG) and in the intesti-
nal washings (sIgA). The results demonstrated that coated chitosan nanoparticles might
have potential for being used as a deliver system for oral vaccination with the recombinant
hepatitis B surface antigen.
last few years, the majority of industrialized countries have1. Introduction
According to a report of the World Health Organization
(WHO/UNICEF, 2005), the estimated number of deaths in the
world in all age groups from diseases preventable by vaccines
in 2002 was 2.1 million, 600,000 deaths being due to hepatitis
∗ Corresponding author. Tel.: +351 239859927; fax: +351 239827126.
E-mail address: olga@ci.uc.pt (O. Borges).
0928-0987/$ – see front matter © 2007 Elsevier B.V. All rights reserved.
doi:10.1016/j.ejps.2007.08.005© 2007 Elsevier B.V. All rights reserved.
B. The global coverage of infants with three doses of hepatitis
B vaccine in 2004 was 48%, contrasting with 3% in 1992. In theintroduced hepatitis B vaccination campaigns. Therefore, the
above statistics of deaths due hepatitis B are representative
predominantly for the less developing countries, where mass
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accination has not been implemented yet (18% of the 192
HOmember states). Its implementation is highly dependent
n the development of more stable and cheaper vaccines for
hich the intervention of specialised human resources for the
dministration would not be required.
Oral administration has been appointed as the only eco-
omically feasible approach to mass vaccination. Impressive
ogistical advantages of orally administered vaccines were
xemplified by two national vaccination days in 1996, when
21 million Indian children were vaccinated against polio at
50,000 centres (Bloom and Widdus, 1998). However, it has
een shown that is very difficult to obtain a protective immune
esponse following oral vaccination, the live-attenuated polio
accines are being one of the few exceptions (Holmgren and
zerkinsky, 2005). For this reason, only few vaccines currently
pproved for human use are being administered orally.
Unfortunately, a simple oral formulation is not easily
chieved for the new generation of subunit vaccines, which
old the greatest promise for disease prevention in the 21st
entury (Thanavala et al., 2005). Several explanations have
een appointed to justify the disappointing results found for
ral administration of subunit vaccines, being almost exclu-
ively biotechnological products. One of the most important
easons is related with the adverse environment of the gas-
rointestinal tract (GIT), rich in acids and enzymes, which are
ble to destroy the antigen. Equally important is the mecha-
ism of oral tolerance, the vital physiological role for dietary
ntigens in preventing hypersensitivity reactions to food or
o commensal bacteria (Mowat, 2003; Nagler-Anderson, 2001).
his hyporesponsivity to antigens orally administered is not
et fully understood, but it is thought that the mucosal
mmune system has involved a variety of mechanisms to
chieve and maintain tolerance against self-antigens and
gainst the overabundance of environmental antigens present
n the microflora and food. Among them, activation-induced
ell death, anergy and especially the induction of regulatory T
ells are frequently reported in the literature (Holmgren and
zerkinsky, 2005). In a recent study (Gotsman et al., 2000) the
nduction of oral tolerance to hepatitis B virus proteins was
chieved by the administration of five low oral doses of hep-
titis B virus proteins, followed by two inoculations with a
ommercial vaccine.
In the case of the development of an oral hepatitis B
accine, this mechanism has to be circumvented and the
ntigen must be protected from physical degradation and
nzymatic digestion (Holmgren and Czerkinsky, 2005). For this
urpose, several strategies have been described in literature.
hose approaches include the encapsulation of immunogenic
eptide representing residues 127–145 of the immunodomi-
ant B-cell epitope of hepatitis B surface antigen (HBsAg) in
oly(d,l-lactide co-glycolide) (Rajkannan et al., 2006). Another
trategies are the encapsulation of the plasmid DNA encod-
nghepatitis B virus protein inpoly(d,l-lactide-co-glycolic acid)
PLGA) (He et al., 2005) or in Salmonella typhimurium (Gao et al.,
003; Woo et al., 2001; Zheng et al., 2001, 2002) or the genetic
odification of edible plants for the production anddelivery ofhe hepatitis B vaccine, within, e.g., potato tubers (Kong et al.,
001; Thanavala et al., 2005), cherry tomatillo (Gao et al., 2003)
nd lettuce (Kapusta et al., 1999, 2001). A very recent clinical
tudy (Thanavala et al., 2005) with previously vaccinated vol-l sc i ences 3 2 ( 2 0 0 7 ) 278–290 279
unteers showed that the ingestion of doses of 100 g uncooked
potato tubes (8.5g/g) induced the increase of the serum anti-
HBsAg titers in about 60% of the volunteers, who ate three
doses of the potatoes. Approximately 40% of the volunteers
were non-responders to the HBsAg, therefore the necessity
of simultaneous finding a good mucosal adjuvant in order to
elicit an increase of the number of responders was empha-
sised by the authors of this study (Thanavala et al., 2005).
So, with this in mind the present study has as a main
purpose, the evaluation of the potential of a chitosan-based
nanoparticulate delivery system as a mucosal adjuvant.
Chitosan, a copolymer of d-glucosamine and N-acetyl-d-
glucosamine is a derivative of chitin, one of the polysaccha-
rides most abundant in nature. In the last few years, the
properties of this biodegradable biopolymer have been inten-
sively investigated. In particular, its ability to stimulate cells
from the immune system has been shown in several studies
(Babensee and Paranjpe, 2005; Borges et al., 2007; Nishimura
et al., 1987; Shibata et al., 1997). For instance, the presence
of chitosan in a dendritic cell culture-induced the expression
levels of the co-stimulatory molecules CD86, CD40 and HLA-
DQ (Babensee and Paranjpe, 2005), indicative of dendritic cell
maturation. Likewise, chitosan has also shown to be able to
up-regulate, in some extent, a number of macrophage func-
tions (Nishimura et al., 1987; Shibata et al., 1997).
The polymer has also been used in the nanoparticle for-
mulation for loading and delivering different vaccines, like
meningococcal C conjugate (Baudner et al., 2002), diphtheria
(van der Lubben et al., 2003) and tetanus toxoid (Jaganathan
et al., 2005; Vila et al., 2004) or used without any modification,
suspending the bulk powder in a solution of the meningococ-
cal C conjugate vaccine (Baudner et al., 2005) or using a soluble
chitosan derivative with the influenza vaccine (Bacon et al.,
2000; Read et al., 2005) or finally using chitosan to surface-
modified PLGA microspheres containing hepatitis B vaccine
for intranasal immunization (Jaganathan and Vyas, 2006).
In a previous study, we have formulated and characterised
alginate-coated chitosan nanoparticles (Borges et al., 2005).
They consist of a chitosan core (chitosan nanoparticles) to
which the hepatitis B vaccine was adsorbed and in a second
step, the sodium alginate. The alginate coating is afterwards
cross-linked with calcium ions. This delivery system has the
particular advantage of being constructed under very mild
conditions, which is a great benefit for the encapsulation of
proteins, peptides and antigens. Moreover, in a very recent
publication (Borges et al., 2006) we have demonstrated that
these coated nanoparticles were able to be taken up by rat
Peyer’s patches which is one of the essential features to inter-
nalise, deliver and target the intact antigen to specialised
immune cells from the gut associated lymphoid tissue (GALT)
(Neutra and Kozlowski, 2006). This property makes these new
nanoparticles a promising delivery system especially for oral
vaccination.
Therefore, in the present study the feasibility of using
the recombinant surface hepatitis B protein (HBsAg) encap-
sulated into the above-mentioned alginate-coated chitosan
nanoparticles for the induction of local and systemic immune
responses after oral vaccination was evaluated. Moreover,
to improve the immune response, synthetic oligodeoxynu-
cleotides containing immunostimulatory CpG motifs (CpG
ut ic280 european journal of pharmace
ODN), were also associated to the formulations, entrapped
or not in the nanoparticles. CpG ODN acts as a potent adju-
vant and has shown in a number of studies to induce a Th1
type immune response, not onlywhen administered parenter-
ally (Osorio et al., 2003; Weeratna et al., 2001) but also after
mucosal vaccination (McCluskie and Davis, 2000; McCluskie et
al., 2000a,b). It has been shown in non-human primates, that
the CpG ODNs improve the immunogenicity of the hepatitis B
vaccine (Klinman et al., 2004). Regarding human clinical expe-
rience with CpG ODNs, limited information concerning the
outcome of these trials has been released. However there are
some few examples already reported in literature (Carpentier
et al., 2006; Cooper et al., 2004; Friedberg et al., 2005). One such
example is a double-blind phase I/II study with CpG 7909, as
adjuvant to Engerix-B designed to evaluate the safety of CpG
7909 in healthy adults (Cooper et al., 2004). According with
the authors of the same study, the most frequently reported
adverse events were injection site reactions, flu-like symp-
toms andheadache. Additionally, as reviewed somewhere else
(Klinman et al., 2004), no clinically relevant changes in hema-
tocrit or white blood cell count among immunized volunteers,
nor were there any changes in liver or renal function and
none of the subjects exposed to CpG ODNs developed signs
or symptoms of autoimmune disease.
Therefore CpGODNhas been regarded as a promising adju-
vant for the hepatitis B vaccine and in the present study the
possible advantages for its encapsulation were in vivo evalu-
ated.
2. Materials and methods
2.1. Materials
2.1.1. Polymers
Ultra pure chitosan was purchased from Primex BioChemicals
AS (Avaldsnes, Norway). According to the provider’s specifica-
tions, the degree of deacetylation is 95% (titration method)
and the viscosity is 8 cP (measured in 1% solutions in 1%
acetic acid). A low molecular weight pharmaceutical grade
sodium alginate (MANUCOL LB®) was kindly donated by ISP
Technologies Inc. (Surrey, UK). According to the provider’s
specifications, the typical values for the percentage of man-
nuronic and guluronic acid for Manucol LB are 61 and 39%,
respectively, with an estimated molecular weight of 18kDa.
2.1.2. Antigen, adjuvant and reagents
The hepatitis B surface antigen (HBsAg) (subtype ADW2) was
kindly offered by GSK Biologicals (Rixensart, Belgium). Class B,
CpGODN (1826) (5′-TCCATGACGTTCCTGACGTT-3′) was pur-
chased from Coley Pharmaceutical Group (Ottawa, Canada).
Concanavalin A (Con A), phenylmethanesulfonyl fluoride
(PMSF), avidin peroxidise conjugate and the BCIP/NBT-purple
liquid substrate system for membrane were from Sigma
Chemicals (St. Louis, USA). Certified fetal bovine serum
(FBS) and l-glutamine (200mM) were from Gibco (Invitrogen
Co., Paisley, Scotland, UK), 1M HEPES buffer (0.85%, NaCl),
RPMI 1640 without l-glutamine and Pen-Strep (10,000U peni-
cillin/ml; 10,000g streptomycin/ml) were from Biowhitaker
(Cambrex Bio Science, Verviers, Belgium). [methyl-3H] thymi-al sc i ences 3 2 ( 2 0 0 7 ) 278–290
dine (1.0mCi/ml) was obtained from Amersham Biosciences
(UK), R-Phycoerythrin (PE)-conjugated hamster anti-mouse
CD69, fluorescein isothiocyanate (FITC)-conjugated rat anti-
mouse CD4 and FITC-conjugated rat anti-mouse CD8 were
obtained from BD Biosciences (Madrid, Spain). The FITC-
conjugated goat anti-mouse IgM (anti-), the anti-mouse
IFN- and biotin rat anti-mouse IFN- was purchased from
PharMingen (San Diego, CA, USA). The mouse IgA ELISA
quantitation kit was obtained from Bethyl Laboratories (Mont-
gomery, USA). All others reagents usedwere analytic grade. All
solutions were prepared in ultrapure water.
2.2. Methods
2.2.1. Preparation of the coated nanoparticles
The preparation of the alginate-coated chitosan nanoparticles
was performed according to the method previously described
by Borges et al. (2005). In brief, chitosanwas dissolved at a con-
centration of 0.25% (w/v) in diluted acetic acid solution. The
formation of the particles was achieved after the addition of
3.5ml of sodium sulfate solution (10%, w/v) to 200ml of the
chitosan solution. The resulting suspension was centrifuged
for 30min at 3500 rpm (2800× g) and the supernatant was dis-
carded. The particles were re-suspended in Millipore water
and centrifuged twice. Finally they were frozen in liquid nitro-
gen and freeze-dried overnight using a Labconco freeze dry
system (Labconco Corporation, Kansas, USA). The dry powder
was kept frozen until further use.
The loading of the nanoparticles with HBsAg or with CpG
ODN was performed separately by incubating a solution of
HBsAg or the solution of CpG with a suspension of chitosan
particles at pH 7.4 (phosphate buffer) under mild agitation at
room temperature during 120min. The resulting suspensions
with the composition of 0.015% (w/v) HBsAg and 0.5% (w/v)
nanoparticles and the second with 0.015% (w/v) CpG and 0.5%
(w/v) nanoparticles were used in the subsequent coating step.
Alginate-coated nanoparticles were obtained by mixing equal
volumes of nanoparticles suspension and a buffer phosphate
solution of sodium alginate (1%, w/v) under magnetic stirring.
The agitation wasmaintained for 20min. The suspension was
then centrifuged for 10min at 1600 rpm and the supernatant
was discarded. The particles were re-suspended in 0.524mM
CaCl2 in 50mMHEPES buffer solution, kept under agitation for
another 10min and immediately administered to the mice.
2.2.2. Evaluation of the loading efficacy of HBsAg and
CpG ODN in coated nanoparticles
The loading efficacy of the coated particles was calculated
by an indirect way, quantifying the antigen that remained in
solution as describedbefore (Borges et al., 2006). After the coat-
ing with alginate, an aliquot of the particle suspension was
centrifuged at 14,000 rpm for 15min and the protein in super-
natant was quantified by micro-BCA-protein assay (PIERCE,
Rockford, USA) using a microplate reader with a 570nm filter.
For the CpGODN the same procedure was followed and the
oligodeoxynucleotides was quantified, measuring the OD of
the supernatants at 260nm. To eliminate background interfer-
ence, the supernatant of unloaded particles were treated the
sameway. The results refer to thenanoparticle batchesused in
the vaccination studies (four batches for each immunization).
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The loading efficacy (LE) and the loading capacity (LC) were
alculated from the following equations:
E (%) = total amountofHBsAgorCpG − freeHBsAgorCpG
total amountofHBsAgorCpG
×100 (1)
C
(
gofHBsAgorCpG
mgchitosannanoparticlesdryweight
)
= total amountofHBsAgorCpG − freeHBsAgorCpG
mgchitosannanoparticlesdryweight
(2)
.2.3. Evaluation of the structural integrity of the vaccine
he integrity of hepatitis B antigen was confirmed using SDS-
olyacrylamide gel electrophoretic (SDS-PAGE) analysis of the
epatitis B vaccine released overnight from the nanoparticles
7.4 pH buffer phosphate; 37 ◦C; 50 rpm). The samples were
entrifuged at 14,000 rpm in order to separate the released
ntigen from the particles and an aliquot was then solu-
ilised with the loading buffer and treated (5min at 100 ◦C).
he SDS-PAGE was performed in accordance with standard
rotocols (Coligan, 2001) with 12% resolving gel, cast and run
n tris–glycine buffer at 25mA and finally stained with silver
itrate.
The antigenicity of the entrapped hepatitis B vaccine was
ssessed by Western blotting using a mouse antiserum raised
gainst the native antigen. The hepatitis B vaccine samples
ere transferred from the unstained gel onto a nitrocellulose
embrane, using semi-dry electroblotting system (115mA;
h) and the membrane was blocked overnight at 4 ◦C with
BS-T (containing 0.05% of Tween 20 and 5% of milk). After
ashing with PBS-T, the membrane was incubated for 2h at
oom temperature with the positive anti-HBsAg IgG mouse
ntiserum, diluted 1:500 in PBS-Twith 5% of low fatmilk. After
ashing with PBS-T, the membrane was incubated with anti-
ouse IgG conjugated to alkaline phosphatase, diluted 1:750.
he ability of the mouse antiserum to recognize hepatitis B
accine released from the nanoparticles was demonstrated
olorimetrically using 5ml of phosphatase buffer with 33l
BT (50g/ml) and 16.7l BCIP (50g/ml). The reaction was
topped by washing the membrane with water.
.2.4. Immunization studies
.2.4.1. Animals. Six-week-old female BALB/c AnNHsd mice
ere used (Harlan Iberica, Barcelona, Spain) with four or six
ice per group. Animals were housed for acclimatization 1
eek before the experiments at the animal resource facil-
ties of the Faculty in accordance with institutional ethical
uidelines. They had free access to food and water, with 12h
ight/dark cycle. Two hours before the oral vaccination and
vernight before the end of the experiment, the mice were
tarved allowing only free access to water..2.4.2. Treatment groups.
Group I: suspension of alginate-coated chitosan nanoparti-
cles loaded with 10g HBsAg;l sc i ences 3 2 ( 2 0 0 7 ) 278–290 281
• Group II: suspension of alginate-coated chitosan nanopar-
ticles loaded with 10g HBsAg plus 10g of the adjuvant
(CpG ODN) in solution;
• Group III: untreated—control;
• Group IV: solution with 10g HBsAg;
• Group V: solution with 10g HBsAg and 10g CpG ODN;
• Group VI: suspension of the mixture of alginate-coated chi-
tosan nanoparticles loaded with 10g HBsAg and particles
loaded with 10g CpG ODN.
2.2.4.3. Immunization schedule. Each animal received imme-
diately before immunization 100l of a 7.5% sodiumbicarbon-
ate solution in order to neutralise the acid environment of the
stomach. The different formulations, corresponding to each
treatment group (see Section 2.2.4.2) were administered orally
with a gavage-feeding needle. The primary immunizationwas
followed by one boost 3 weeks later with 150l volume con-
taining 10g of the vaccine. The animals were sacrificed 10
days post-boost and a collection of blood from the heart,
vaginal secretions, small intestinal washes and the spleen
was carried out for analysis as described in the following
sections.
2.2.4.4. Collection of samples. Blood samples were taken from
the orbital sinus before the boost and by cardiac puncture
at the end of the experiment and the sera were prepared by
centrifugation and stored at −20 ◦C until analysis.
Vaginal and gutwasheswere obtained by rinsingwith (75l
3×) 225l and 600l cold PBS (containing 0.1% sodium azide,
0.1%bovine serumalbumin (BSA) and 1mMPMSF) through the
vagina or the intestine, respectively. The extract was vortexed,
allowed to stay at room temperature for 15min and then cen-
trifuged (6000 rpm/15min/4 ◦C). The clear supernatants were
stored at −80 ◦C until analysis.
2.2.4.5. Enzyme-linked immunosorbent assays (ELISA)
for HBsAg-specific immunoglobulins. Ninety-six-well flat-
bottomed microtiter plates (Nunc immunoplate maxisorb)
were previously coated (incubated overnight at 4 ◦C) with
the recombinant HBsAg (1g/well) in coating buffer (50mM
sodium carbonate, pH 9.6). The plates were washed five times
with PBS-T (PBS containing 0.05% Tween-20) and blocked
with 3% BSA in PBS-T (200l/well) during 1h at 37 ◦C. The
plates were then washed five times with PBS-T and the
serial dilutions of each serum (100l/well) from the individ-
ual mice were tested in triplicate, starting from a dilution
1:100 in PBS-T. The serum was incubated during 2h at 37 ◦C
and after washing the plates with PBS-T, the plates were
incubated for additional 30min at 37 ◦C with peroxidase-
labeled goat anti-mouse immunoglobulin G and isotypes
(anti-IgG1, anti-IgG2a, anti-IgG2b and anti-IgG3). The bound
antibodies were revealed adding 100l/well of 0.5mg/ml of
O-phenylenediamine dihydrochloride (OPD) (Sigma, Spain) in
10ml of citrate buffer with 10l of H2O2. The reaction was
stopped after 10min with 50l of 3M HCl to each well. The
absorbance was read out at 492nm in an automatic ELISA
reader (Easy Reader 400, SLT-LABINSTRUMENTS). Elisa titers
were expressed as mIU/ml and 1mIU is the OD mean of the
pre-immune serum plus two times the standard deviation.
ut ic282 european journal of pharmace
The measurement of IgA was carried out using a mouse
IgA ELISA quantification kit (Bethyl Laboratories,Montgomery,
Texas, USA) as described by the manufacturer. In order to
make a correct evaluation of the sIgA in the gut and vagi-
nal extracts, total sIgA and the specific anti-HBs sIgA were
determined in the extracts. The results are presented as the
anti-HBsAg IgA/total IgA. By this way differences between
samples related with the extraction process or stability of the
sIgA were minimized.
The IgA standard was diluted to appropriate concentra-
tions in PBS with 1% BSA to create a calibration curve. The
gut washes were diluted in PBS-T with 1% BSA and added
to the plates in series of twofold dilutions. The concentra-
tions of the total and specific IgA were determined from the
calibration curve generated for each set of samples using a
four-parameter logistic curve-fit generated by SigmaPlot soft-
ware (version 8.0, SPSS Inc.).
2.2.4.6. Preparation of spleen cell suspensions. The mice were
euthanized by cervical dislocation and their spleens were
aseptically removed. Individual spleen cell suspensions were
prepared in a Petri dish using curved needles and washed
twice with RPMI 1640. The final suspension was adjusted to
a final concentration of 1×107 cells/ml in complete RPMI 1640
medium (supplemented with 10% (v/v) fetal bovine serum
(FBS), 1% (v/v) glutamine, 1% (v/v) Pen-Strep and 2% (v/v) 1M
HEPES buffer).
2.2.4.7. Cell population of the spleen. The cells
(0.025×107 cells) were washed twice with cold PBS-
supplemented with 2% FBS and then incubated in the
dark for 30min at 4 ◦C with saturated concentrations of
FITC-conjugated rat anti-mouse CD4 or FITC-conjugated rat
anti-mouse CD8 or FITC-conjugated goat anti-mouse IGM
(anti-). After incubation, cells were washed three times with
PBS–2% FBS and then re-suspended in 500l PBS–2% FBS. To
exclude dead cells, 2.5l propidium iodide (50g/ml) were
added just before data acquisition. At least 10,000 events were
analysed by flow cytometric acquisition, performed in a flu-
orescent activated cell sorter (FACS Calibur) (BD, Biosciences,
Madrid, Spain). Data were analysed by CellQuest software
(BD, Biosciences, Madrid, Spain).
2.2.4.8. Splenocyte cell culture in the presence of the mitogens.
Using sterile 96-well flat-bottomed tissue culture plates, 25l
of splenocyte suspension (1×107 cells/ml) from each mouse
was plated in triplicate along with 25l of a complete RPMI
solution of the mitogen (con A (50g/ml), CpG ODN (50g/ml)
plus HBsAg (25g/ml) and HBsAg (25g/ml) alone). A fourth
group of experiments were incubated with 25l of a complete
RPMI solution without any mitogen (negative control). Finally
the volume of all the wells was completed to 200l with com-
plete RPMI and incubated at 37 ◦C with 95% relative humidity
and in the presence of 5% CO2.
2.2.4.9. Cytokine production by splenocytes. Spleen cell sus-
pensions were plated with the mitogens (see Section 2.2.4.8)
and incubated in a humidified 5% CO2 incubator for 24h (IL-2)
and 86h (INF-) at 37 ◦C. The plates were centrifuged and the
supernatants stored at −80 ◦C until analysis.al sc i ences 3 2 ( 2 0 0 7 ) 278–290
IL-2 and IFN- cytokines produced by splenocytes were
determined by ELISA, following a technique described else-
where (Cordeiro-da-Silva et al., 2004).
2.2.4.10. Evaluation of the CD69 expression on lymphocytes.
After 20h of incubation in the presence of different mito-
gens (see Section 2.2.4.8), cells werewashed and re-suspended
in cold phosphate buffered saline (PBS) supplemented with
2% FBS (PBS–2% FBS), resulting in a concentration of
0.5×106 cells/well. The cells were then incubated in the
dark for 30min at 4 ◦C with saturated concentrations of PE-
conjugated hamster anti-mouse CD69 and FITC-conjugated
rat anti-mouse CD4 or FITC-conjugated rat anti-mouse CD8 or
FITC-conjugated goat anti-mouse IGM (anti-). After incuba-
tion, cells were washed three times with PBS–2% FBS and then
re-suspended in 500l of PBS–2% FBS. To exclude dead cells,
2.5l propidium iodide (50g/ml) was added just before data
acquisition. The flow cytometry determinations were done
according to the description given above (see Section 2.2.4.7).
2.2.4.11. Lymphoproliferation assay. Splenocytes were
obtained and cultured together with the mitogens in a
flat-bottomed 96-well plate as described before (see Section
2.2.4.8). The cells were cultured for 96h at 37 ◦C and on the
last 8h of incubation; each well was pulsed with 1Ci of
[methyl-3H] thymidine. 96 well plates with the cells were
stored at −20 ◦C until further analysis. The cells were later
thawed and harvested onto a fiberglass filter (filter mats,
molecular devices, Skatron, Lier, Norway) using a semiau-
tomatic cell harvester (Scatron Instruments, USA) and DNA
thymidine incorporation was counted by standard liquid
scintillation techniques with a Beckman LS 6500 scintillation
counter (Beckman Coulter Inc., Fullerton, USA). Thymidine
incorporation was expressed as counts per minute (cpm).
2.3. Statistical analysis
Data were presented as the mean±S.E.M. for at least three
experiments and statistical significance was assessed using
one-way ANOVA followed by Dunnett’s post-test using the
GraphPad Prism 4 software. Differences were considered sig-
nificant when p<0.05.
3. Results
3.1. Characterization of the alginate-coated
nanoparticles
In a recent publication of our group (Borges et al., 2005),
the development of alginate-coated chitosan nanoparti-
cles and the characterization of this new delivery system
were reported. Briefly, before coating with sodium algi-
nate, the chitosan nanoparticles have a mean diameter of
643nm (dynamic light scattering technique) and are posi-
tively charged (+37mV). Scanning electron microscopy (SEM)
images of uncoated particles also revealed the presence of
small nanoparticles (around 100nm) and demonstrated that
the majority of the coated particles were in a range between
300 and 600nm (Fig. 1 ). The presence of the alginate coating
european journal of pharmaceut ical sc i ences 3 2 ( 2 0 0 7 ) 278–290 283
F icles
a
l
o
c
a
o
o
t
p
r
t
b
f
i
3
c
D
c
(
e
t
a
e
8
i
(
a
d
i
o
s
3
h
T
n
tig. 1 – Scanning electron micrographs of chitosan nanopart
fter the coating with sodium alginate.
ayer was confirmed both by FTIR and DSC studies and by the
bservation of the inversion of the zeta potential to −34mV.
Ovalbumin release studies from coated and uncoated
hitosan nanoparticles, performed with several pH buffers,
llowed us to conclude that the coating with sodium alginate
f the ovalbumin loaded chitosan nanoparticles avoided an
valbumin burst release observed in the first 30min compared
ouncoated chitosannanoparticles at pH5.5; 6.8 and7.4 (phos-
hate buffer) (Borges et al., 2006). However at pH 1.2, a burst
elease was observed for both coated and uncoated nanopar-
icles. For this reason in the present study a 7% sodium
icarbonate solution was administered immediately before
eeding the mice with the nanoparticles with the purpose to
ncrease the pH of the stomach fluids.
.2. CpG ODN and hepatitis B antigen entrapment in
oated nanoparticles
ifferent ratios of hepatitis B vaccine to chitosan nanoparti-
les and CpGODN to chitosan nanoparticleswere investigated
data not shown) and the systems with the highest loading
fficacy were used for the further studies. It could be shown
hat hepatitis B antigen and CpG ODN were efficiently associ-
ted with alginate coated chitosan nanoparticles. The loading
fficacy of hepatitis B vaccine in the coated nanoparticles was
5.9±4.7% (mean±S.D.) and the mean of the loading capac-
ty was 25.7g HBsAg/mg of dry chitosan nanoparticles ±1.42
S.D.). The loading efficacy of CpGwas even better, 98.8±1.29%
nd the loading capacity 29.85±0.0364 (g CpG ODN/mg of
ry chitosan nanoparticles) since the existence of a strong
nteraction between DNA or oligodeoxynucleotides and the
ppositely charged cationic chitosan has already been demon-
trated (Danielsen et al., 2005; Hillberg and Tabrizian, 2006).
.3. Confirmation of the structural integrity of
epatitis B antigenhe adsorption of hepatitis B antigen (HBsAg) to chitosan
anoparticles occurred at room temperature, under mild agi-
ation using a phosphate buffer as the external medium of: (A) after freeze-dry and re-suspending in water and (B)
the suspension. The coating with alginate was done under
similar conditions, being considered as non-aggressive for the
entrapment of ODNs, proteins, peptides and vaccines. Never-
theless, a SDS-PAGE analysis followed by a Western blotting
was performed in order to confirm the integrity of hepatitis B
antigen and the results are shown in Fig. 2 . SDS-PAGE anal-
ysis of the bulk vaccine showed the presence of a dominant
band with a molecular weight below 30kDa (Fig. 2b, lane 1)
that, according to the literature, was identified to be the 24kDa
polypeptide described by Stephenne (1990) and a second pro-
teinwith amolecularweight between 35 and 55kDa. The same
gel revealed identical bands for the entrapped HBsAg (lanes
2–4) and there were no additional bands to indicate the pres-
ence of fragments. Therefore the integrity of the antigen was
not affected by the entrapment procedure.Moreover theWest-
ern blot membrane shown in Fig. 2a demonstrated that the
HBs-specific antibodies from a serum of a vaccinated mouse
recognized the antigen epitopes (Fig. 2a, lanes 3–5) in a similar
way as for the bulk vaccine (Fig. 2a, lanes 1 and 2), confirming
that the antigenicity of the hepatitis B antigen was not altered
after the entrapment into nanoparticles.
3.4. Evaluation of cellular immune responses
3.4.1. Lymphoproliferative response
The cellular immune response of individual mice was evalu-
atedmeasuring in vitro proliferation of splenocytes, incubated
in the presence of HBsAg or in the presence of HBsAg plus
CpG or in the presence of ConA (positive control), respectively.
Cells cultured without mitogens were used as a negative con-
trol of the experiment and showedas expectedonly lowcounts
perminute (cpm) values (data not shown). Similar to the nega-
tive controlwere the results obtainedwith cells incubated only
with the antigen (data not shown). The lymphoproliferation in
vitro induced by themixture of the hepatitis B antigen and the
immunopotentiator CpGODNwere evaluated in all the groups
and are shown in Fig. 3A . The cellular proliferation observed
in all the groups was probably caused by the presence of CpG,
since it was previously demonstrated that the HBsAg alone in
the concentration used did not induce any proliferative effect.
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Fig. 2 – Western blot and SDS-PAGE analysis of the released hepatitis B antigen from alginate-coated chitosan
nanoparticles. (a) Western blot—lane 1: molecular weight markers; lane 2: HBsAg before association with particles in PBS;
lanes 3–5: HBsAg after association with coated nanoparticles and subsequently released overnight in PBS at 37 ◦C. (b)
ith
n PBSDS-PAGE silver stained—lane 1: HBsAg before association w
coated nanoparticles and subsequently released overnight i
The same Fig. 3A showed that the group I (HBsAg associated
with nanoparticles) and group VI (HBsAg and CpG associated
with nanoparticles) presented a lower splenocyte proliferative
capability when compared with the control group. Neverthe-
less, due to the large variability of the results, the values are
not statistically different from the control group. Even less or
no proliferation was observed in group IV (HBsAg in solution)
and group V (HBsAg and CpG in solution).
Finally, Fig. 3B shows the lymphoproliferative results
observed in the presence Con A, a classical mitogen, which
served as a positive recall antigen. The groups II, IV and V pre-
sented cpm values between 20,000 and 60,000, similar to the
control group (group III). These results contrasted with those
found for the groups I and VI, where a much stronger prolifer-
ative responsewas observed, showing values between 100,000
and 180,000 cpm.
3.4.2. Cell populations
The evaluation of spleen cell populations was done immedi-
ately after sacrificing the mice. Each individual value and the
means for each group are shown in Fig. 4 . The percentage of
CD4+ T lymphocytes showed to be similar in all groups. On
the other hand, slight but statistically differences were found
in the CD8+ T-lymphocyte populations in some treated groups
when comparedwith the control group. In particularly the per-
centage of CD8+ T-lymphocytes appeared slightly increased in
groups IV and V and decreased in groups I and VI.
The increase of the CD8+ T lymphocytes with the decrease
of the CD4+/CD8+ ratio as well as a significant decrease of
the lymphocyte proliferative response to antigen stimulation,
appear to be correlated with the immunological tolerance
phenomena (Fanta et al., 1999). The groups IV and V, wherethe particles; lanes 2–4: HBsAg after association with
S at 37 ◦C.
antigen or the antigen plus the adjuvant were given in solu-
tion, were shown to fulfil these two conditions. On the other
hand the associationof the antigenwithnanoparticles (groups
I, II and VI) may have circumvented this undesirable mech-
anism. Additional studies have to be performed to test this
hypothesis.
3.4.3. Cytokines production
IL-2 and IFN-were assayed in the supernatants from spleno-
cytes cultured in the presence of different mitogens (HBsAg,
Con A and the mixture of HBsAg+CpG ODN) and the results
are shown in Fig. 5 . The highest IL-2 mean levels were found
in groups I and VI. Nevertheless these results are not statisti-
cally significant due to the high variability within the groups.
The production of IFN- by the splenocytes was detected in all
the groups in the presence of different mitogens. However the
highest mean value was detected in the group VI, where CpG
and the antigen were administered associated to the coated
nanoparticles, with CpG ODN as the main responsible fac-
tor for the high IFN- production. Therefore, the formulation
given to the group VI seemed to be the most effective in the
generation of a Th1 profile of immune response.
3.4.4. Expression of the early activation marker CD69
CD69 is a type IImembrane protein expressed as a homodimer
of heavily glycosylated subunits. Both T and B cells begin to
express CD69 within a few hours after stimulation, being rec-
ognized as an early activationmarker antigen of lymphocytes.
In the present study the expression of CD69 in splenocytes of
individual mice was evaluated after 20h incubation with dif-
ferent mitogens, being the assay with Con A as the positive
control of the experiment (Fig. 6D ).
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Fig. 3 – Lymphoproliferative response after oral
administration of the different hepatitis B vaccine
formulations. In vitro proliferation of individual mouse
spleenocytes during a 96h period stimulated with: (A)
HBsAg+CpG ODN; (B) Con A. Each circle represents the
result of individual samples and the horizontal bar the
mean of the group. The results corresponded to thymidine
i
(
m
i
e
o
T
c
a
e
w
l
Fig. 4 – Percentage of T-lymphocytes CD4+, CD8+ and B+
lymphocytes in the spleens of mice from the treatment
groups (I, II, IV–VI) and the control (naı¨ve mice) group (III)
determined by FACS analysis. Each bar corresponds to the
group geometric mean plus the standard error of the mean
(n between 3 and 6). The comparison between the control
group (III) and the different treatment groups (I, II, IV–VI)
was made with a one-way analysis of variance (ANOVA)
followed by Dunnett’s multiple comparison test (**p<0.01ncorporation and are expressed as counts per minute
cpm).
Cells from the spleen without in vitro stimulation, nor-
ally exhibit low levels of CD69 expression as demonstrated
n Fig. 6A. In spite of that, significant differences in the CD69
xpression on CD4+ T lymphocytes between group I (p<0.01)
r group VI (p<0.01) and the control group were observed.
he splenocytes were collected 10 days after the boost and
ultured for 20h without stimulation, which is considered as
long period between the antigen exposure and the CD69
xpression. These significanthigher valueswere also observed
ith HBsAg (Fig. 6B) and HBsAg+CpG (Fig. 6C) in vitro stimu-
ated splenocytes. Despite of the lower CD69 expression levelsand *p<0.05).
observed on cells (without in vitro stimulation the values were
around 5% and 13–18%) the concordance of the three assays
(Fig. 6A–C) gave consistency to the results observed for the
groups I and VI. Moreover, in the same groups lower percent-
ages of B lymphocytes CD69+ (8.4 and 7.1% for the groups I
and VI, respectively) were observed when compared with the
control group (17%) (Fig. 6A and B). This result correlates well
with the above described lymphoproliferative assay (see Sec-
tion 3.4.1), where the B lymphocytes showed lower capability
to proliferate.
Finally, in the same in vitro study it was observed that the
CD8+ T-lymphocytes from the groups I and VI, incubated in
the presence of theHBsAg andCpGODN, expressed significant
higher percentage of CD69 molecule (9.7% and 12.9% for the
groups I and VI, respectively) when comparedwith the control
group (3.6%).
3.5. Humoral immune response
3.5.1. Systemic antibody response
Serum from the mice was collected before the first immu-
nization and before and after the boost and analysed for the
anti-HBsAg IgG. The results are shown in Fig. 7 . With only
one boost, two of three groups orally vaccinated with the
antigen associated with coated nanoparticles were able to
show seroconversion. In fact, the group I vaccinated with the
HBsAg associated with coated nanoparticles showed a very
low responder number (1/6) whereas the group VI, with the
antigen and the adjuvant associated with the nanoparticles
showed a better result (2/5). This last result wasmost probably
related with the presence of the also encapsulated adjuvant.
IgG subclass titresweremeasured in respondermice before
and after the boost (data not shown). Oral immunization with
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Fig. 5 – Cytoquine production by splenocytes of individual
mice from each treatment group: (A) IL-2 secretion from
splenocytes cultured for 24h in presence of Con A; (B) IFN-
secretion from splenocytes cultured for 86h in the absence
or in the presence of different mitogens (HBsAg; Con A;
HBsAg+CpG ODN). Each bar corresponds to the group
geometric mean plus the standard error of the mean (n
between 3 and 6). The comparison between control group
(III) and the different treatment groups (I, II, IV–VI) was
made using a one-way analysis of variance (ANOVA)
Fig. 6 – Expression of the CD69 antigen on B and T
splenocytes from different mouse groups in response to
different in vitro stimulation. The stimulus experienced
were the immunostimulators, CpGODN (histogram C) and
Con A (positive control; histogram D), the antigen, HBsAg
(histograms B and C) or without in vitro stimuli (histogram
A). The values are mean±S.E.M. of the percentage of the
positive CD4 cells that express the CD69 antigen, obtained
from individual mice of each group (n between 3 and 6).followed by Dunnett’s multiple comparison test (**p<0.01
and *p<0.05).
HBsAg loaded nanoparticles (group I) induced a Th2 humoral
immune response profile (Ig1 > Ig2a+ Ig2b), however after the
boost, the titres of Ig2a+ Ig2b (Th1)were stronger, nevertheless
lower than Ig1 (Th2). This mixed Th1/Th2 profile of response
has been attributed to the HBsAg on its own (Weeratna et al.,
2000). On the other side, the oral immunization with the anti-
genplus the adjuvant-loadednanoparticles (groupVI) induced
a Th1 profile humoral immune response, attributed to the
presence of the CpG ODN (Weeratna et al., 2001). This kind of
immune response, normally associatedwith a strong immune
cell response, has been claimed for the control of intracellular
infections. This includes viral infections, similar to infections
with the hepatitis B virus (Rehermann and Nascimbeni, 2005).
3.5.2. Mucosal anti-HBsAg sIgA
The results of the determination of the IgA in gut washes are
shown in Fig. 8 . These results are presented as ratio between
the amount of the specific IgA and the total IgA present in the
washes of the gut of each mouse. No significant anti-HBsAg
The comparison between control group (III) and the
different treatment groups (I, II, IV–VI) was made with the
one-way analysis of variance (ANOVA) with Dunnett’s
multiple comparison test (**p<0.01 and *p<0.05).
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Fig. 7 – Serum anti-HBsAg IgG titres of mice immunized
with different oral formulations of hepatitis B vaccine.
Values are expressed as antibody titres of individual mice
taken before the boost and after the boost. Titres were
defined as the highest plasma dilution resulting in an
absorbance value twice that of non-immune plasma
(1mlU/ml=mean+2S.D. of the control group).
Fig. 8 – Secretory anti-HBsAg sIgA profile detected in
individual intestine washing samples of mice immunized
with different hepatitis B vaccine oral formulations. Each
circle represents the result of individual samples and the
horizontal bar the mean of the group. Samples with the
value equivalent to mean plus twice the S.D. of the control
group (group III), were considered anti-HBsAg sIgA positive.
The values were expressed as the ratio between the
anti-HBsAg sIgA (ng/ml) and total sIgA (g/ml).l sc i ences 3 2 ( 2 0 0 7 ) 278–290 287
IgA was detected in the gut of mice immunized with the solu-
tions of the antigen (groups IV and V). In contrast, detectable
anti-HBsAg IgA was quantified in gut washes of some mice
from groups I and VI (Fig. 8).
4. Discussion
It has been suggested that the response to orally administered
antigens is initiated locally in the gut and then disseminated
to the secondary lymph nodes and spleen, while other groups
suggest a simultaneous activation of antigen-specific T cells
throughout the animal after feeding the antigen (Smith et al.,
2002). Following these thoughts, it was investigated if a short
time oral vaccination scheme with different formulations of
hepatitis B antigen was able to induce not only mucosal but
also a systemic (cellular and humoral) immune response. One
of the parameters studied was the CD69 expression on the
B and T lymphocytes from the spleen. CD69 is a cell mem-
brane receptor andhasnot been very oftenused in vaccination
experiments. On the other hand, in a short time study, where
an extended immune response is not expected, the investi-
gation of an early activation marker may be useful to quickly
evaluate different antigen formulations.
In the present study, the administration of the hepatitis B
vaccine entrapped in alginate-coated chitosan nanoparticles
was investigated. In some cases (groups I and VI), those for-
mulations were able to induce a cellular immune response,
translated by the highest percentage of CD4+ T-lymphocytes
expressing the CD69 and the lowest percentage of CD69+ B
cells. Moreover, in the same groups, the CD8+ T-lymphocytes
have shown to be the most susceptible to CD69 induction
when cultured in the presence of the antigen plus the adju-
vant. Furthermore, the lymphocytes from those groups (I and
VI) also have shown the highest capacity to proliferate and in
some cases to produce IL-2 and IFN-. This cellular immune
response was accompanied by the presence of IgG and IgA
HBsAg specific in the serum and on the intestinal mucosa,
respectively, however with the presence of non-responder
mice within the groups (I and VI). In the recent literature
(McCluskie et al., 2000a,b), the presence of non-responder
orally or even nasally vaccinated mice is frequently reported,
especially when the evaluation of the specific antibodies was
performed after a single immunization. Moreover, to have
a high percentage of seroconverted mice within the groups
orally vaccinated, it has been always necessary to administer
higher antigen concentrationswith successive administration
of the vaccine. Commercial injectable hepatitis B vaccines also
have this drawback in humans (Rendi-Wagner et al., 2006). It
was estimated that the priming doses only induce detectable
levels of antibodies in 70–90% of healthy infants, adolescents
and adults. The final boost of the vaccine induces protective
levels of anti-HBs antibodies inmore than 95% (Rendi-Wagner
et al., 2006) of infants and adolescents. In our study, the vac-
cination with a solution with 10g of the antigen (groups IV
and V) did not induce cellular or humoral immune response
and the results shown in this work allowed us to hypothe-
size that immunological tolerance might have been induced.
In fact, oral tolerance has been one of the principal obsta-
cles to different strategies designed for the oral administration
ut ic
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of the vaccines and its induction seems to be related with
the antigen dose (Gotsman et al., 2000; Pecquet et al., 2000)
and also most probably with the intrinsic properties of the
antigen. Identical to our results obtained with a solution of
the antigen were found in literature (McCluskie and Davis,
2000). Even when the dose was increased to 100g, the vac-
cine given orally did not induce at all or in some cases only
low anti-HBsAg IgG titers (McCluskie et al., 2000b). However,
the association of CpG ODN (McCluskie et al., 2000b) or of
PLG microparticles (Rajkannan et al., 2006) to the same high
dose of the vaccine-induced a systemic and mucosal immune
response.
In order to obtain an immune response, the increase of
the antigen dose used may not be sufficient to produce
immunological acceptable results. Moreover, those high con-
centrations may not be economically attractive and hence
different solutions have to be explored. The development of
efficient adjuvants for the mucosal route is one of the more
promising approaches. One of the examples was recently
described in the literature, the CpG ODN. A number of studies
have shown that the CpGODN is an effective immunomodula-
tor molecule for parenteral (McCluskie et al., 2001a; Weeratna
et al., 2001) and mucosal routes (McCluskie et al., 2000a,b,
2001b,c). Moreover, CpG ODN has been shown to induce Th1
profile immune responseswith a number of different antigens
(Diwan et al., 2002; Weeratna et al., 2001).
In the present study, the profile of the immune response,
observed in the group VI, vaccinated with the hepatitis B anti-
gen and the CpG ODN, both associated with nanoparticles,
was re-directed to a Th-1 profile, when comparedwith the Th-
2 immune response observed in group I (vaccinated just with
the antigen associatedwith the nanoparticles). Additionally, it
was observed an increase of the percentage of respondermice
when the CpG ODN encapsulated was included in the formu-
lation (group VI). Therefore, this formulation (group VI) may
also have a promising potential for the improvement of the
currently licensed HBV vaccines, in particular to make them
useful also in the treatment of chronic hepatitis B, where is
required a strong Th-1 cellular immune response induction.
Nevertheless it would be worth examining if the controlled
delivery of the antigen and the CpG ODN from the chitosan
nanoparticles is also able to enhance the longevity of the
immune response.
Themechanism of adjuvant action of CpG ODN is not com-
pletely understood, but it is known that CpG ODN binds to the
toll-like receptor 9 (TLR-9) (McCluskie and Weeratna, 2006).
Therefore the immunostimulator effect is mediated only after
its cell internalization (Diwan et al., 2002). On the other hand,
the entrapment of CpG into nanoparticles with a size larger
than a cell, may fail to stimulate immune cells, most probably
because the nanoparticles cannot be internalised.
The physical proximity of the antigen and the adjuvant
seems to be a requirement for an effective adjuvant effect
(Davis et al., 1998). This hypothesis could be the key, at least
in part, of the lack of an early immune response observed
in our study with the group of mice treated with the anti-
gen associated with the nanoparticles and the adjuvant in
solution (group II). The hepatitis B antigen associated to the
nanoparticles and the adjuvant in solution may have been
taken up in different regions of the intestine. According toal sc i ences 3 2 ( 2 0 0 7 ) 278–290
our own previous studies (Borges et al., 2006), alginate-coated
chitosan nanoparticles can be taken up by Peyer’s patches
and the CpG ODN in solution was most probably internalized
by the enterocytes. On the contrary in the group VI, antigen
and adjuvant, both associated to the nanoparticles, were
most probably internalized simultaneously by M-cells of the
Peyer’s patches and this fact may explain the better results
observed in this group.
5. Conclusion
Alginate-coated chitosan nanoparticles are able to entrap effi-
ciently the hepatitis B recombinant vaccine and the CpG ODN
used as an adjuvant.
Humoral and cellular immune response were better
induced in mice vaccinated with the formulation where
the antigen and the adjuvant appeared associated with the
nanoparticles. The Th1 profile immune response induced by
this formulation is crucial in preventing or overcoming hepati-
tis B infections, thus making this delivery system a promising
one. However further studies and in time prolonged with
additional boosts have to be done in order to evaluate the
appearance of desirable new responder mice. Also it has to
be demonstrated whether a long lasting cellular and humoral
immune response can be induced with this formulation using
this challenging oral administration route.
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